NO20076468L - Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger - Google Patents
Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetningerInfo
- Publication number
- NO20076468L NO20076468L NO20076468A NO20076468A NO20076468L NO 20076468 L NO20076468 L NO 20076468L NO 20076468 A NO20076468 A NO 20076468A NO 20076468 A NO20076468 A NO 20076468A NO 20076468 L NO20076468 L NO 20076468L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- methods
- preparing
- cox
- inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000007918 intramuscular administration Methods 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 208000025978 Athletic injury Diseases 0.000 abstract 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000008765 Sciatica Diseases 0.000 abstract 1
- 201000002661 Spondylitis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1357DE2005 | 2005-05-27 | ||
| PCT/IN2006/000177 WO2006126214A2 (en) | 2005-05-27 | 2006-05-25 | Injectable compositions and process for preparation of such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076468L true NO20076468L (no) | 2008-02-27 |
Family
ID=36917368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076468A NO20076468L (no) | 2005-05-27 | 2007-12-14 | Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1895983A2 (es) |
| JP (1) | JP2008542260A (es) |
| KR (1) | KR20080016689A (es) |
| CN (1) | CN101217939A (es) |
| AU (1) | AU2006250765A1 (es) |
| BR (1) | BRPI0611170A2 (es) |
| CA (1) | CA2609242A1 (es) |
| CR (1) | CR9616A (es) |
| EA (1) | EA200702646A1 (es) |
| MX (1) | MX2007014862A (es) |
| NO (1) | NO20076468L (es) |
| RS (1) | RS20070461A (es) |
| TN (1) | TNSN07482A1 (es) |
| WO (1) | WO2006126214A2 (es) |
| ZA (1) | ZA200711068B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103181893A (zh) | 2007-09-07 | 2013-07-03 | 联合治疗公司 | 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法 |
| KR20140014350A (ko) * | 2009-03-12 | 2014-02-06 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 정맥 내 투여용 이부프로펜의 투여 |
| US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
| CN102335114B (zh) * | 2010-07-23 | 2015-07-15 | 重庆医药工业研究院有限责任公司 | 一种稳定的布洛芬精氨酸注射剂及其制备方法 |
| CN102370615B (zh) * | 2010-08-19 | 2013-09-04 | 四川科伦药物研究有限公司 | 一种布洛芬注射制剂及其制备方法 |
| WO2013058303A1 (ja) | 2011-10-18 | 2013-04-25 | ラクオリア創薬株式会社 | 医薬組成物 |
| CN102512383A (zh) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | 供注射用的帕瑞昔布钠药物组合物 |
| US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CN103372216B (zh) * | 2012-04-26 | 2015-05-06 | 北京京卫燕康药物研究所有限公司 | 一种含有塞来昔布的固体药物组合物 |
| TWI646091B (zh) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | 鹽類及晶形 |
| US20140187635A1 (en) | 2012-12-28 | 2014-07-03 | Themis Medicare Limited | Diclofenac compositions |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN103263385B (zh) * | 2013-05-17 | 2016-04-27 | 江苏正大清江制药有限公司 | 一种塞来昔布长效纳米注射剂及其制备方法 |
| US20180000940A1 (en) * | 2014-12-20 | 2018-01-04 | Troikaa Pharmaceuticals Limited | Injectable formulations of paracetamol |
| WO2016170401A1 (en) * | 2015-04-20 | 2016-10-27 | Umedica Laboratories Pvt. Ltd | Novel injectable composition of diclofenac sodium |
| CN107303266B (zh) * | 2016-04-18 | 2020-09-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦注射液及其制备方法 |
| CN107303264A (zh) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | 无泡沫左旋奥拉西坦注射液及其制备方法 |
| FR3077984B1 (fr) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | Composition multiusage de torasemide |
| CN109498852B (zh) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | 治疗骨科疾病的生物降解材料及其应用 |
| CN111103381A (zh) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | 一种液质联用测定人血浆中尼美舒利浓度的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389681A (en) * | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1283252B1 (it) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | Soluzioni di piroxicam iniettabili per via parenterale |
| IN187306B (es) * | 1998-01-12 | 2002-03-23 | Panacea Biotec Ltd | |
| PE20021017A1 (es) * | 2001-04-03 | 2002-11-24 | Pharmacia Corp | Composicion parenteral reconstituible |
| AU2003249510A1 (en) * | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
-
2006
- 2006-05-25 BR BRPI0611170-0A patent/BRPI0611170A2/pt not_active IP Right Cessation
- 2006-05-25 AU AU2006250765A patent/AU2006250765A1/en not_active Abandoned
- 2006-05-25 KR KR1020077030585A patent/KR20080016689A/ko not_active Ceased
- 2006-05-25 ZA ZA200711068A patent/ZA200711068B/xx unknown
- 2006-05-25 WO PCT/IN2006/000177 patent/WO2006126214A2/en not_active Ceased
- 2006-05-25 RS RSP-2007/0461A patent/RS20070461A/sr unknown
- 2006-05-25 CN CNA2006800250937A patent/CN101217939A/zh active Pending
- 2006-05-25 JP JP2008513009A patent/JP2008542260A/ja not_active Withdrawn
- 2006-05-25 CA CA002609242A patent/CA2609242A1/en not_active Abandoned
- 2006-05-25 EP EP06756263A patent/EP1895983A2/en not_active Withdrawn
- 2006-05-25 MX MX2007014862A patent/MX2007014862A/es not_active Application Discontinuation
- 2006-05-25 EA EA200702646A patent/EA200702646A1/ru unknown
-
2007
- 2007-12-14 NO NO20076468A patent/NO20076468L/no not_active Application Discontinuation
- 2007-12-19 CR CR9616A patent/CR9616A/es not_active Application Discontinuation
- 2007-12-21 TN TNP2007000482A patent/TNSN07482A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0611170A2 (pt) | 2010-08-17 |
| ZA200711068B (en) | 2009-03-25 |
| CA2609242A1 (en) | 2006-11-30 |
| JP2008542260A (ja) | 2008-11-27 |
| CN101217939A (zh) | 2008-07-09 |
| CR9616A (es) | 2008-10-30 |
| WO2006126214A2 (en) | 2006-11-30 |
| WO2006126214A3 (en) | 2007-06-07 |
| TNSN07482A1 (fr) | 2009-03-17 |
| AU2006250765A1 (en) | 2006-11-30 |
| KR20080016689A (ko) | 2008-02-21 |
| EA200702646A1 (ru) | 2008-06-30 |
| MX2007014862A (es) | 2008-02-21 |
| EP1895983A2 (en) | 2008-03-12 |
| RS20070461A (sr) | 2008-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076468L (no) | Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger | |
| CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
| DK1742624T3 (da) | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet | |
| CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
| MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| NO20060424L (no) | 5-heteroringbaserte P38 kinaseinhibitorer | |
| DK1505973T3 (da) | Kombinationer til behandling af multipelt myelom | |
| ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
| MX2010002278A (es) | Farmacos antivirales para el tratamiento de una infeccion por arenavirus. | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| NO20051726L (no) | Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser | |
| ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| BR112013026202A2 (pt) | composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank | |
| SV2009003283A (es) | Inhibidores de la actividad de la akt | |
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| JOP20240235A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
| ATE542800T1 (de) | Kinasehemmer und ihre anwendungsverfahren | |
| ATE527243T1 (de) | Calciumkanal-antagonisten vom typ chinazolinon t | |
| EA200901237A1 (ru) | Применение димирацетама при лечении хронической боли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |